

Cumulative Index 1990

Volume 10

March	TUMOR MARKERS IN DIAGNOSTIC PATHOLOGY, pages 1-260
June	CLINICAL TOXICOLOGY I, pages 261-439
September	CLINICAL TOXICOLOGY II, pages 441-647
December	MYELOPROLIFERATIVE DISORDERS, pages 649-925

Note: Page numbers of article titles are in **boldface** type.

- A2B5 antigen, as tumor marker, 167-168, 171
- ABL** gene, in leukemia, 840-842, 845-851
- ABL** nuclear kinase, in myelopoiesis, 781
- Absorption, of alcohol, 356
- of aluminum, 407
- of drugs, in overdose, 261-262, 264-265
- Accounting. *See Cost analysis.*
- Acetaminophen, nephrotoxicity of, 337-338
- overdose of, serum concentrations in, 267
- treatment of, 265
- N-Acetyl-L-cysteine, in acetaminophen overdose, 265
- Acid phosphatase, in leukemia classification, 665-666
- in myeloid leukemia diagnosis/treatment, 714-715
- Acidosis, in toxic cell injury, 319
- Actin, as tumor marker, 64, 188
- Activated charcoal, in drug overdose treatment, 264-265
- Adenine nucleotides deficiency, in platelets, in myeloproliferative disorders, 878-879
- Adenocarcinoma, tumor markers in, in undifferentiated neoplasm, 71-72
- monoclonal antibody detection of, 81
- vulvovaginal, 107
- Adenoma, pituitary, tumor markers in, 40, 43, 54-55
- Adenosine triphosphate, depletion/inhibition of, in toxic cell injury, 318-319, 538
- Adrenal gland tumors, tumor markers in, 52-53
- Adulteration, of drug testing specimens, 514
- AE 1 and 3 antibodies, in adenocarcinoma diagnosis, 81
- in cerebrospinal fluid studies, 91
- Aggregation testing (platelets), in myeloproliferative disorders, 880-882
- Agnogenic myeloid metaplasia, laboratory findings in, 831-835
- Agnogenic myeloid metaplasia-idiopathic myelofibrosis, platelet disorders in, 873-876, 878
- Alcohol, **355-374**
- absorption of, 356
- abuse of, blood lead levels in, 444
- blood concentration of, after last drink, 356-357
- breath test for, 356-357
- driving performance/regulations and, 356-358, 360-362, 364, 367
- in postabsorption phase, 356
- in preabsorption phase, 356
- industrial accidents and, 364-366
- legal limit for driving, 360-362
- medical treatment and, 361, 363
- units for, 358
- vs. age, 368-369
- vs. gender, 369
- vs. plasma concentration, 358
- vs. subjective feelings, 366
- vs. time, 356
- vs. urine concentration, 358, 372
- consumption of, average daily ounces of ethanol index for, 367
- drinking level index for, 367

Alcohol (*Continued*)

- estimation of, 370-371
- determination of, in testing programs, 371-372
- in urine, 371-372
- methods for, 361-362
- specimen processing for, 358, 360
- validity of, 360-361
- distribution of, 355-357, 369-371
- excretion of, 370
- metabolism of, 369-371
- pharmacokinetics of, 369-371
- pharmacology of, 581-582
- postmortem testing for, 581-584
- toxicity of, acute, 363
- chronic, 363
- vs. driving performance, 367
- death in, 367
- impairment determination in, 360
- signs and symptoms of, 360, 364
- tolerance to, 366-368

Alkaline phosphatase, in myeloid leukemia diagnosis/treatment, 715-716

Allergenicity assay, of biomedical polymers, 554, 556

- Alpha-fetoprotein, as tumor marker, 3-6
- combined use of, 17
- in central nervous system metastases, 175
- in germ cell neoplasms of nervous system, 174-175
- in ovarian neoplasms, 113
- in retinoblastoma, 172

Aluminum, 403-433

- clinical importance of, 403
- determination of, procedure for, 427-432
- sample collection in, 426-427
- distribution of, in serum, 408
- gastrointestinal absorption of, 407
- in dialysate, 406-407
- in foods, 404-405
- in medications, 405-406
- in water, 405
- sources of, 404-407
- toxicity of, 423-426

- Alzheimer's disease and, 409, 423
- anemia in, 414-415
- deferoxamine in, 417
- in chronic renal failure, 409-416
- in dialysis, 410-414
- in industrial exposure, 408
- in nonindustrial exposure, 409
- metastatic calcification in, 415-416
- organ accumulation in, 416
- parathyroid hormone and, 407, 424
- vitamin D and, 407

Alzheimer's disease, aluminum and, 409, 423

Ames test, of biomedical polymers, 552-553

Amikacin, ototoxicity of, 342

Aminoglycosides, nephrotoxicity of, 329-330

ototoxicity of, 339-343

Amiodarone, digoxin interaction with, 489

AML. See *Myeloid leukemia, acute*.

Amphetamines, determination of, in urine, 301-308, 493-494, 496-497, 500

Amphotericin B, nephrotoxicity of, 331

Analgesics, nephrotoxicity of, 337-338

ototoxicity of, 345-346

Androgens, in myelodysplastic syndrome, 699

Anemia, in chronic renal failure, aluminum role in, 414-415

in myelodysplastic syndromes, 685

in myeloproliferative disorders, 826

refractory, chromosomal abnormalities in, 759

in myelodysplastic syndromes, 686, 689-694

Angioblastic meningioma, tumor markers in, 158

Angioendotheliosis, tumor markers in, 163

Angiosarcoma, tumor markers in, 187-188

ANLL. See *Nonlymphocytic leukemia, acute*.

Antacids, aluminum in, 405-406

Anti-oncogenes, 771

Antibiotics. See *Antimicrobial agents*.

Antibodies. See also *Monoclonal antibodies*; specific antibody.

44-3A6, in lung neoplasia, 85

to carcinoembryonic antigen, 64-65

to epithelial membrane antigen, 65, 79-81, 83, 86

to GCDFP-15, 65-66

to muscle actin (HHF35), 64

to neuron-specific enolase, 67-68

to T200, 67

α -Antichymotrypsin, as tumor marker, in skin tumors, 188

in vulvovaginal neoplasms, 108

in granulocytic sarcoma diagnosis, 894

Antidotes, for drug overdose, 266

Antigens, of acute myeloid leukemia cells.

See *Immunophenotyping*.

Antileukocyte common antigen, in granulocytic sarcoma diagnosis, 895

Antimalarial drugs, ototoxicity of, 346

Antimicrobial agents, digoxin interaction with, 489

nephrotoxicity of, 329-332

ototoxicity of, 347

Antineoplastic drugs. See also *Chemotherapy*.

nephrotoxicity of, 332-333

ototoxicity of, 343-344

Antipyretics, ototoxicity of, 345-346

α -Antitrypsin, as tumor marker, in vulvovaginal neoplasms, 108

in granulocytic sarcoma diagnosis, 894

- Apocrine gland tumors, tumor markers in, 106, 183-184
- Appendage tumors of skin, tumor markers in, 182-186
- Arachidonic acid, in toxic cell injury, 317-318
- metabolism of, in myeloproliferative disorders, 881-882
- Arsenic, 459-472
- absorption of, 463
 - analysis for, 470-471
 - biochemistry of, 465-466
 - biotransformation of, 465
 - chemistry of, 462-463
 - distribution of, 463, 465
 - excretion of, 465
 - historical use of, 460-461
 - sources of, 461-462
 - toxicity of, 345, 398
 - acute, 467
 - chronic, 467-469
 - lethal dose of, 467
 - mechanism of, 466
 - treatment of, 469-470
 - vs. chemical form, 463
- Arsenolysis, 466
- Arsine, chemistry of, 463
- toxicity of, 461
 - acute, 469
 - chronic, 469
 - mechanism of, 466
 - treatment of, 470
- Arterial oxygen saturation, reduced, polycythemia in, 860
- Aspirin, nephrotoxicity of, 337
- Astrocytoma, tumor markers in, 164, 166-167
- Atomic absorption spectrometry, in aluminum determination, 427-432
- ATP. See *Adenosine triphosphate*.
- Auer rods, in acute myeloid leukemia, 661
- Automation, in information management, 239-240
- Autopsy, toxicologic studies in. See *Forensic toxicology, postmortem*.
- Autotransfusion, polycythemia in, 862
- B6.2 antibodies, in breast cancer diagnosis, 88
- B72.3 antibodies, in breast cancer diagnosis, 88
- in epithelial neoplasm diagnosis, 80
 - in lung neoplasia, 84
 - in peritoneal washing cytology, 82-83
- B cell(s), development of, 120-123
- B cell markers, in lymphoma, 202-204
- B cell neoplasms, gene rearrangements in, 129
- tumor markers in, 23-25
- gene translocations, 27
- Bacitracin, nephrotoxicity of, 331
- Basal cell carcinoma, tumor markers in, 180-181
- BCR-ABL fusion gene, in leukemia, 830, 840-845, 848-852
- bcr test, for Philadelphia chromosome, 842-845
- Bence-Jones protein, as tumor marker, 1-2
- Benzodiazepines, urine testing for, 494
- 34-beta-E12 antibodies, in cerebrospinal fluid studies, 91
- Beta-glucuronidase, as tumor marker, 175
- Beta₂-microglobulin, as astrocytoma marker, 166
- Bile, for postmortem toxicology testing, 574
- Biomedical polymers, biocompatibility/toxicology of, 549-570
- allergenic potential test, 554, 556
 - bovine aortic tissue tests, 559
 - carcinogenic potential assay, 553-554
 - cell growth inhibition test, 552
 - corneal implantation test, 557-558
 - cumulative toxicity index in, 556
 - hemolysis test, 551
 - in brain tissue, 564-566
 - intracutaneous rabbit test, 552
 - intramuscular rabbit implant test, 551-552
 - mutation assay, 552-553, 559, 562
 - poly[bis(-carboxyphenoxy) alkane anhydrides], 556-566
 - subcutaneous tests, 558-559, 562-564
 - teratogenic potential assay, 553, 562
 - tissue culture-agar overlay test, 550-551
- Biopsy specimens, fine needle aspiration, tumor markers in, 83-89
- Bismuth, nephrotoxicity of, 335
- BL99-57, in lung neoplasia, 84
- Blast crisis, in chronic myelogenous leukemia, 831
- markers for, 211
- Blood, collection of, for postmortem toxicology testing, 573-574
- Blood alcohol concentration. See under *Alcohol*.
- Blood group HO, as tumor marker, 181
- Blood group isoantigens, as tumor markers, 109
- Bombesin, as tumor marker, 44
- Bone, growth hormone effects on, 474
- lead levels in, 455-456
 - metabolic disease of, in dialysis, 411-415, 423-426
- Bone marrow, cytogenetic studies of, 756-757
- in agnogenic myeloid metaplasia, 832-835
 - in chronic myelogenous leukemia, 830

- Bone marrow (*Continued*)
 in myelodysplastic syndromes, 687-689
 in myeloproliferative disorders, 827
 myelopoiesis in, 653, 655
 transplantation of, in myelodysplastic syndrome, 699
 purging agents for, 816-817
 tissue evaluation in, 816
- Bowenoid papulosis, tumor markers for, 181
- Brain tumors. *See also Nervous system tumors.*
 tumor markers in, 89-91
- Breast cancer, tumor markers in, 9
 monoclonal antibody detection of, 88
 receptor proteins, 66, 114
- Breath tests, for alcohol, 354-355
- Bromodeoxyuridine, in leukemia cell assay, 819-820
- Bronchogenic carcinoma, tumor markers in, 47
- Bumetanide, nephrotoxicity of, 333
 ototoxicity of, 343-345
- Buprenorphine, metabolism of, 381-382
- Burst-forming units, in myelopoiesis, 651
- Busulfan, in chronic myelogenous leukemia blast crisis, 816
- C-cell neoplasms, tumor markers in, 46
- Ca antigens, as tumor markers, in uterine neoplasms, 110
- Ca 1 antigen, as tumor marker, antibodies to, 79
- Ca 2 antigen, as tumor marker, antibodies to, 80
- Ca 3 antigen, as tumor marker, antibodies to, 80
- Ca 15-2 antigen, as tumor marker, 15-16
- Ca 19-9 antigen, as tumor marker, 16
- Ca 50 antigen, as tumor marker, 16-17
- Ca 125 antigen, as tumor marker, 16, 112
- Cadmium, nephrotoxicity of, 334
- Calcification, metastatic, in aluminum toxicity, 415-416
- Calcineurin, as tumor marker, 170, 172
- Calcitonin, as tumor marker, 44, 48-51
- Calcitonin gene-related peptide, as tumor marker, 51
- Calcium, homeostasis of, in toxic cell injury, 319-320
 in cell growth, 540-542
 in neoplasia, 540-542
 lead interaction with, 446-447
 measurement of, in toxic cell injury, 533-536
 regulation of, in toxic cell injury, 531-547
- Calcium ionophores, in toxic cell injury, 538-539
- Cancer markers. *See Tumor markers.*
- Cannabinoids, urine testing for, 493-494, 496-497, 500
- Capreomycin, ototoxicity of, 347
- Capsid antigen, monoclonal antibodies to, 92-93
- Captopril, nephrotoxicity of, 336
- Carbohydrates, as tumor markers, 17
- Carbon monoxide poisoning, polycythemia in, 860, 862
 postmortem testing for, 579-581
- Carboplatin, nephrotoxicity of, 332-333
- Carboxyhemoglobin, postmortem testing for, 579-581
- Carcinoembryonic antigen, as tumor marker, 8-9, 48-49
 combined use of, 17, 21
 in central nervous system metastases, 175
 in cervical neoplasms, 109
 in choroid plexus tumors, 160
 in epidermal tumors, 181
 in germ cell neoplasms of nervous system, 175
 in immunohistochemistry, 64-65
 in meningioma, 156
 in ovarian neoplasms, 112
 in retinoblastoma, 172
 in skin appendage tumors, 183-184, 186
 in uterine neoplasms, 110
 in vulvovaginal neoplasms, 106
 monoclonal antibodies to, 78-79, 81, 83
 structure of, 9
- Carcinogenesis, calcium regulation in, 541-542
 of biomedical polymers, assay of, 553-554
- Carcinoid, tumor markers in, 46-47, 110, 113
- Carcinomatosis, meningeal, tumor markers in, 175
- Carcinosarcoma, tumor markers in, 110-111
- Cardiotoxicity, of digoxin, 482, 487
- Carotid body tumor, tumor markers in, 174
- Cathartics, in drug overdose treatment, 265
- CD antigens, in leukemia diagnosis, 740-742
 on myeloid cell surface, leukemic, 727-732
 normal, 723-727
- CD2 antigen, as Hodgkin's disease marker, 206
 in acute myeloid leukemia blasts, 729
- CD3 antigen, as Hodgkin's disease marker, 206
 as lymphoma marker, 203
- CD5 antigen, as lymphoma marker, 203
 in acute myeloid leukemia blasts, 729
- CD7 antigen, as leukemia marker, 208, 211, 745

- CD11b antigen, in acute myeloid leukemia blasts, 727
- CD11/18 antigen, in myeloid cells, 725-726
- CD13 antigen, as leukemia marker, 208, 727
- CD14 antigen, in acute myeloid leukemia blasts, 727-728, 731
- in myeloid cells, 723, 725
- CD15 antigen, as Hodgkin's disease marker, 205-207
- as leukemia marker, 208, 727, 730-732
- in myeloid cells, 725
- CD16 antigen, in myeloid cells, 726
- CD19 antigen, as Hodgkin's disease marker, 206
- as leukemia marker, 208-211
- as lymphoma marker, 203-204
- CD22 antigen, as Hodgkin's disease marker, 206
- as lymphoma marker, 203-204
- CD25 antigen, as Hodgkin's disease marker, 205-207
- CD30 antigen, as Hodgkin's disease marker, 205-207
- CDw32 antigen, in myeloid cells, 726-727
- CD33 antigen, as leukemia marker, 208
- in acute myeloid leukemia blasts, 727, 729-730, 732
- CD34 antigen, in acute myeloid leukemia blasts, 727-728, 730-731
- in undifferentiated acute leukemia, 744-745
- CD45 antigen, as Hodgkin's disease marker, 205
- CD64 antigen, in acute myeloid leukemia blasts, 727
- in myeloid cells, 726-727
- CE 400 antibodies, in cervical neoplasms, 92
- CE 407 antibodies, in lung neoplasia, 84
- Cell growth inhibition test, of biomedical polymers, 552
- Cell injury mechanisms, toxic, 311-321, 531-547
- activated oxygen species in, 313-315
- calcium homeostasis in, 319-320
- covalent binding hypothesis of, 312-313
- glutathione in, 315
- interacting biochemical events in, 311-312
- membrane phospholipid catabolism in, 316-318
- mitochondrial energy metabolism in, 318-319
- protein thiols in, 315-316
- targets of injury in, 312
- Cephalosporins, nephrotoxicity of, 330
- Cerebrospinal fluid, monoclonal antibody studies of, 89-92
- tumor markers in, 175
- Cervical neoplasms, tumor markers in, 92-93, 109-110
- Chelation therapy, in arsenic poisoning, 469-470
- Chemicals, ototoxicity of, 346
- Chemotherapy. *See also Antineoplastic drugs.*
- in myelodysplastic syndromes, 699
- in myeloproliferative disorders, efficacy testing of, 813-817
- myelodysplastic syndromes resulting from, 695-696
- nephrotoxicity of, 332-333
- ototoxicity of, 343-344
- Chief Information Officer. *See Hospital information management.*
- Chlorambucil, in polycythemia vera, 866
- Chlorinated hydrocarbons, toxicity of, 400-401
- Chloroacetate esterase, in myeloid leukemia diagnosis/treatment, 712-713
- Chloroleukemia. *See Granulocytic sarcoma.*
- Chloroma. *See Granulocytic sarcoma.*
- Chloroquine, ototoxicity of, 346
- Chordoma, tumor markers in, 174
- Choriocarcinoma, tumor markers in, 6, 111
- Choroid plexus tumors, tumor markers in, 159-160
- Chromatography, cost analysis of, 594-597
- gas. *See Gas chromatography/mass spectrometry.*
- in drug testing, 493-501
- in postmortem forensic toxicology, 576-578, 583-584
- Chromogranins, as tumor markers, 45-46
- in cervical neoplasms, 110
- in immunohistochemistry, 67
- in ovarian neoplasms, 113
- in uterine neoplasms, 110
- in vulvovaginal neoplasms, 108
- Chromosomal abnormalities. *See also Philadelphia chromosome.*
- as tumor markers, 26, 134
- in acute myeloid leukemia, 755-767, 775
- in agnogenic myeloid metaplasia, 835
- in chronic myelogenous leukemia, 830-831
- in granulocytic sarcoma, 897
- in myelodysplastic syndromes, 684, 688, 755-767
- in myeloproliferative disorders, proto-oncogenes and, 786-790
- nomenclature in, 757-758
- Cimetidine, nephrotoxicity of, 332
- Cisplatin, nephrotoxicity of, 332-333
- ototoxicity of, 343-344
- CK series of antibodies, in lung neoplasia diagnosis, 85
- Clonidine, metabolism of, 382-383

- Clonogenic assays, clinical outcome and, 810-812
- CML. See *Myelogenous leukemia, chronic*.
- Cocaine, urine testing for, 301-308, 493-494, 496-497, 500
- Coelomic epithelium-related glycoprotein, as tumor marker, 112
- Colony-forming units, in myelopoiesis, 650-651, 722-723
- leukemic, assays for, 809-816
- Colony-stimulating factors, in myelodysplastic syndrome treatment, 699
- in myelopoiesis, 651, 653, 655-657, 773-776
- Colorectal cancer, tumor markers in, 9
- Common leukocyte antigen, as tumor marker, 106, 162-163
- in immunohistochemistry, 67
- Complement activation, in toxic cell injury, 539
- Computer information management. See *Information systems*.
- Condyloma acuminatum, tumor markers in, 180-182
- Connective tissue, growth hormone effects on, 474-475
- Contrast media, nephrotoxicity of, 335-336
- Coroners' system. See *Forensic toxicology, postmortem*.
- Cost analysis, in toxicology laboratory, 591-623
- accounting concepts in, 599-602
- algorithm for, 592
- capital costs in, 600
- direct materials costs in, 605-606, 608
- general cost allocation, 616, 618
- indirect costs in, 603
- instrument cost accounting in, 602-616
- labor costs in, 610, 613
- method comparison in, 592
- operational costs in, 601
- sectional, 613, 616
- uses of, 618-621
- variance from budget and, 621
- vs. laboratory section, 613
- vs. methodology, 592, 594-599
- information systems in. See *Information systems*.
- Covalent binding hypothesis, in toxic cell injury, 312-313
- Criminal investigation. See *Forensic toxicology, postmortem*.
- CSF-1 receptors, 776-777
- Cumulative toxicity index, of biomedical polymers, 556
- Cyclosporine, nephrotoxicity of, 325-326
- Cytochemistry, in myeloid leukemia diagnosis/treatment, 707-720
- of acute leukemia, 664-666, 738-739
- Cytogenetics, of agnogenic myeloid metaplasia, 835
- of chronic myelogenous leukemia, 830-831
- of granulocytic sarcoma, 896-898
- of myelodysplastic syndromes, 755-767
- Cytokeratin. See *Keratins*.
- Cytology, of granulocytic sarcoma, 892-893
- Cytopenia, in agnogenic myeloid metaplasia, 832
- in myelodysplastic syndromes, 685, 689-698
- Cytoplasmic filaments. See *Filaments, cytoplasmic*.
- Cytosine arabinoside, in leukemia, efficacy of, 814-815, 818-820
- in myelodysplastic syndrome, 699
- D6.1 antibodies, in malignant melanoma diagnosis, 86
- 2D1 antibodies, in epithelial neoplasm diagnosis, 79
- Data management. See *Hospital information management; Information systems*.
- DDT, toxicity of, 400-401
- Deferoxamine, in aluminum toxicity, 417
- Delta-aminolevulinic acid dehydrase, lead effects on, 448, 454
- Delta-aminolevulinic acid synthetase, lead effects on, 448
- Dementia, in aluminum toxicity, 409
- in dialysis, 410-411
- Department of Defense, drug testing program of, 520
- Department of Health and Human Services, drug testing guidelines of, 518-520
- Department of Transportation, drug testing program of, 520, 522
- Dermatofibroma/fibrosarcoma, tumor markers in, 108
- Desmin, as tumor marker, in cerebrospinal fluid studies, 91
- in immunohistochemistry, 63-64
- in uterine neoplasms, 110-111
- in vulvovaginal neoplasms, 108
- Dialysis, aluminum toxicity in, 406-407, 410-414
- encephalopathy in, 410-411, 423-425
- in drug overdose treatment, 265-266
- osteodystrophy in, 411-415
- Diamine oxidase (histaminase), as tumor marker, 47-48
- Digital imaging fluorescence microscopy, in toxic cell injury study, 531-547
- Digoxin, 479-492
- absorption of, 484
- biotransformation of, 485-486
- distribution of, 484-485

- drug interactions with, 488-490
- elimination of, 486-487
- historic aspects of, 481
- indications for, 480-481
- mechanism of action of, 481
- pharmacodynamics of, 487
- toxicity of, 482-483
- Dimercaprol, in arsenic poisoning, 469
- Distribution, of drugs, alcohol, 355-357,
369-371
 - aluminum, 408
 - in overdose, 262-263
- Diuretics, digoxin interaction with, 489
 - in drug overdose treatment, 265
 - nephrotoxicity of, 333
 - ototoxicity of, 344-345
- DNA, enzymatic digestion of, 143-144
 - eukaryotic, isolation of, 140-143
 - hybridization of. See also *In situ hybridization*.
 - in human papillomavirus detection, 181
- DNA polymerase alpha, as tumor marker, 109
- DNA polymerase chain reactions, as tumor markers, 31-32, 135
- DNA stains, in acute myeloid leukemia cell phenotyping, 722
- Driving performance/regulations, alcohol blood concentration and, 356-358, 360-362, 364, 367
- Drug(s), aluminum in, 405-406
 - consumption of, in elderly population, 479-480
 - nephrotoxic. See *Nephrotoxic agents*.
 - ototoxic. See *Ototoxic agents*.
 - overdose of, pharmacokinetics of, 261-269
 - absorption in, 261-262, 264-265
 - antidotes and, 266
 - distribution in, 262-263
 - excretion in, 264-266
 - metabolism in, 263, 265
 - serum concentrations and, 267-268
- Drug abuse. See also *Opiates, dependency on*.
 - nephrotoxicity in, 333
 - testing in, confirmation, 493-502
 - mandatory, 517-529
 - postmortem, 584-586
 - quality assurance in, 503-516
 - screening, 493-502
 - urine, 301-308
 - population trends and, 289-299
- Drug-Free Workplace Act of 1988, 519
- Drug testing, confirmation procedures in, 493-502
 - cross-reactivity in, 498-500
 - federal regulations concerning, 518-522
 - in urine, gas chromatography/mass spectrometry in, 271-288
 - interferences in, 498-500
 - liability in, 527-528
 - mandatory, 517-529
 - medical review officer role in, 522-529
 - method performance data in, 497-498
 - postmortem. See *Forensic toxicology, postmortem*.
 - quality assurance in. See *Quality assurance*.
 - record keeping in, 527
 - retesting in, 526
 - sample collection in, 494
 - screening procedures in, 493-502
 - sensitivity of, 495-496
 - specificity of, 498-499
 - split sample collection in, 526-527
 - verification procedures in, 525
- Dyserythropoiesis, in myelodysplastic syndromes, 686
- Dysgerminoma, tumor markers in, 113
- Dysgranulopoiesis, acute myeloid leukemia and, 677-678
 - in myelodysplastic syndromes, 686
- Dysmegakaryocytopoiesis, acute myeloid leukemia and, 677-678
 - in myelodysplastic syndromes, 687
- Ear, toxic injury of. See *Ototoxic agents*.
- Eccrine gland tumors, tumor markers in, 106, 183-184
- Effusions, monoclonal antibody studies of, 78-82
- Elderly persons, digoxin use in, 479-492
 - nephrotoxic drugs and, 324
- Electron microscopy, in granulocytic sarcoma, 895-896
 - in leukemia classification, 666
 - in leukemia of indeterminant lineage, 739
- Electrophoresis, in lymphoid neoplasms, 135-136
 - pulsed-field, in Philadelphia chromosome detection, 846-847
- Embryonal carcinoma, tumor markers in, 6, 113
- Emesis, in drug overdose treatment, 264
- Encephalopathy, dialysis, aluminum in, 410-411, 423-426
- Endocrine malignancies, tumor markers in, 39-57
 - chromogranins, 45-46
 - enzymes, 47-48
 - hormones, 39-45
 - multiple endocrine neoplasia syndromes, 49-55
 - oncodevelopmental antigens, 48-49
- Endodermal sinus tumor, tumor markers in, 113
- Endothelial neoplasms, tumor markers in, 108

- Enzyme immunoassay, cost analysis of, 599
in drug testing, 493-494, 498
- Enzymes, as tumor markers, 47-48
- Eosinophil(s), function of, 649
- Eosinophilia, in myelomonocytic leukemia, 671
- Eosinophilic myelocytes, in granulocytic sarcoma, 691
- Ependymoblastoma, tumor markers in, 168
- Ependymoma, tumor markers in, 168
- Epidermal growth factor receptor, in myelopoiesis, 778
- Epidermal tumors, tumor markers in, 180-182
- Epinephrine aggregation, of platelets, in myeloproliferative disorders, 881
- Epinephrine/dopamine ratio, as tumor marker, 53
- Epithelial cell antigens, as tumor markers, 174
- Epithelial membrane antigen (human milk fat globule protein), antibodies to, 78-81, 83, 86
as tumor marker, antibodies to, 79-81
in choroid plexus tumors, 159-160
in ependymoma, 168
in epidermal tumors, 181
in immunohistochemistry, 64-65
in meningioma, 156, 158
in nerve sheath tumors, 155-156
in ovarian neoplasms, 111, 113
in skin appendage tumors, 183-184, 186
in uterine neoplasms, 110-111
in vulvovaginal neoplasms, 106-107
monoclonal antibodies to, 78
- Epithelial neoplasms, tumor markers in, 62-63
in undifferentiated neoplasm, 68, 71-72
monoclonal antibodies to, 78-80
ovarian, 111-112
uterine, 110
vulvovaginal, 106-108
- EPO proto-oncogene, in myeloproliferative disease, 789
- EPS cytoplasmic kinase, in myelopoiesis, 782
- erb* oncogene, in myeloproliferative disorders, 778
- erbB-2* (*neu*) oncogene, as tumor marker, 30-31, 93-94
- Erythemia (polycythemia vera), 863-869, 873-874, 876-878
- Erythrocyte(s), function of, 649
- Erythrocyte protoporphyrin, lead levels and, 451-453
- Erythrocytosis. *See Polycythemia.*
- Erythroleukemia, acute, 672-673
thyroid hormone receptors in, 778
- Erythromycin, ototoxicity of, 347
- Erythropoietin, in myelopoiesis, 655-657
in polycythemia, 859-862
- Esterases, in leukemia classification, 710-713
nonspecific, 665, 710-712
specific, 665, 712-713
- Etheshioneuroblastoma, tumor markers in, 170
- Estrogen receptor proteins, as tumor markers, in immunohistochemistry, 66
in ovarian neoplasms, 114
monoclonal antibody detection of, 88-89
- Ethacrynic acid, nephrotoxicity of, 333
ototoxicity of, 344-345
- Ethanol. *See Alcohol.*
- Ethylene glycol, nephrotoxicity of, 336
- ETS proto-oncogene, in myeloproliferative disease, 788-789
- EVI-1 proto-oncogene, in myeloproliferative disease, 789-790
- Excretion, of drugs, in overdose, 264-266
- Factor VIII-related antigen, as tumor marker, in gliosarcoma, 166
in hemangioblastoma, 159
in meningioma, 158
in vulvovaginal neoplasms, 108
- Fat metabolism, growth hormone effects on, 475
- Fc receptors, on myeloid cell surface, 726-727, 881
- Ferrochelatase activity, lead effects on, 448, 451
- FES cytoplasmic kinase, in myelopoiesis, 782
- Fetus, lead levels in, 449
- FGR proto-oncogene, in myelopoiesis, 781
- Fibroblasts, tumor markers in, 188
- Fibrohistiocytic neoplasms, tumor markers in, 108
- Fibronectin, as gliosarcoma marker, 166
- Fibroxanthoma, tumor markers in, 108
- Filaggrin, as tumor marker, 181
- Filaments, cytoplasmic (intermediate), as tumor markers. *See also specific type, e.g., Desmin; Keratins.*
in cerebrospinal fluid, 90-91
in epidermal tumors, 180
in immunohistochemistry, 61-64, 79
in lung neoplasia, 85-86
monoclonal antibody detection of, 85, 87
- Fine needle aspiration biopsy specimens, tumor markers in, 83-89
- Fire fatality, carbon monoxide poisoning in, 579-581
- Fleurettes, in retinoblastoma, 171

- Flexner-Wintersteiner rosettes, in retinoblastoma, 171
- Flow cytometry, in acute myeloid leukemia cell phenotyping, 722
- in cancer detection, 94
- in platelet size distribution determination, 875
- Fluorescent probes, in calcium ion measurement, 533-536
- fms oncogene, in myeloproliferative disorders, 777
- FMS proto-oncogene, receptors for, 776-777
- Food, aluminum in, 404-405
- Food and Drug Administration, drug assay regulation by, 493-494, 496-497
- Forensic toxicology, postmortem, 571-589
- analytical principles in, 575-579
- chromatography in, 576-578
- drug testing in, 584-586
- ethanol analysis in, 581-584
- extraction techniques in, 575-576
- in carbon monoxide poisoning, 579-581
- laboratory role in, 572-573
- specimen acquisition in, 573-575
- spectrophotometry in, 576
- volatile substance analysis in, 581-584
- FOS proto-oncogene, in myelopoiesis, 784
- French-American-British Cooperative Group classification, of leukemias, 662-675, 891
- chromosomal abnormalities and, 759
- cytochemistry in, 664-666
- immunophenotyping in, 666-667
- M0 (acute myeloblastic leukemia without cytologic maturation), 667-668
- M1 (acute myeloblastic leukemia with minimal maturation), 668
- M2 (acute myeloid leukemia with significant maturation), 668-669
- M3 (acute promyelocytic leukemia), 669-670
- M4 (acute myelomonocytic leukemia), 670-671
- M4-Eo (acute myelomonocytic leukemia with eosinophilia), 671
- M5a and M5b (acute monocytic leukemia), 671-672
- M6 (acute erythroid myelomonocytic leukemia with eosinophilia), 671
- M5a and M5b (acute monocytic leukemia), 671-672
- M6 (acute erythroleukemia), 672-673
- M7 (acute megakaryoblastic leukemia), 673-674
- reproducibility of, 674-675
- surface antigens correlated with, 728-729
- of myelodysplastic syndromes, 689-698
- Fura-2 probe, in calcium ion measurement, 533-536
- Furosemide, nephrotoxicity of, 333
- ototoxicity of, 344-345
- G proteins, in myelopoiesis, 782-783
- Gaisbock's syndrome, polycythemia and, 862
- Galactocerebroside, as oligodendrogloma marker, 167-168
- Ganglio type of cancer carbohydrates, 17
- Ganglioneuroblastoma, tumor markers in, 170
- Ganglioneuroma, tumor markers in, 170, 174
- Gangliorhabdomyosarcoma, tumor markers in, 170
- Gas chromatography, cost analysis of, 594-596
- in alcohol determination, 583-584
- in postmortem forensic toxicology, 577, 583-584
- Gas chromatography/mass spectrometry, in drug testing, 493, 495, 497-498, 508-510
- in urine drug testing, 271-288
- capabilities of, 274-275
- chemical ionization in, 279-282
- electron ionization in, 276-277
- full-scan analysis in, 275-279
- ion trap detection in, 283-285
- professional standards in, 272-273
- quadrupole system in, 282-283
- selected ion monitoring in, 277-279
- solids probe in, 282
- tandem mass spectrometry and, 285-287
- Gas liquid chromatography, in drug testing, 493
- Gastric lavage, in drug overdose treatment, 264
- Gastrin-releasing peptide, as tumor marker, 44
- Gastrinoma, tumor markers in, 54
- CAWK protein, as tumor marker, 45-46
- GCDFP. See *Gross cystic disease fluid protein*.
- Gel electrophoresis, pulsed-field, in Philadelphia chromosome detection, 846-847
- Gene(s). See also *Oncogenes*; *Proto-oncogenes*.
- amplification of, as tumor markers, 27
- expression of, hybridization techniques and, 229
- mutation of, in granulocytic sarcoma, 897
- translocations of. See also *Philadelphia chromosome*.
- as tumor markers, 27

- Gene(s) (*Continued*)
 tumor suppressor, 771
- Genetic markers, as tumor markers, 26
- Genotyping, in leukemia of indeterminant lineage, 742-743
- Gentamicin, ototoxicity of, 342
- Germ cell neoplasms, tumor markers in, 6, 113-114, 174-175
- Germanium, nephrotoxicity of, 334-335
- Gestational trophoblastic disease, tumor markers in, 111
- GFAP. See *Glial fibrillary acidic protein*.
- Giant cell neoplasms, tumor markers in, 164-168
- Glafenin, nephrotoxicity of, 338
- Glandular neoplasms, cervical, tumor markers in, 109
- Glial cell neoplasms, tumor markers in, 164-168
- Glial fibrillary acidic protein, as tumor marker, in astrocytoma, 164, 166-167 in cerebrospinal fluid, 90-91 in ependymoma, 168 in immunohistochemistry, 64 in ovarian neoplasms, 113 in retinoblastoma, 171
- Gliomatosis peritonei, tumor markers in, 113
- Gliosarcoma, tumor markers in, 166
- Globo type of cancer carbohydrates, 17
- Glomerular changes, from nephrotoxic agents, 326-336
- Glomus tumor, tumor markers in, 174, 187-188
- Glucocorticoids, in myelodysplastic syndromes, 815-816
- Glutamine synthetase, as astrocytoma marker, 166
- Glutathione peroxidase-reductase system, in toxic cell injury, 313-315
- Glycoproteins, platelet, in myeloproliferative disorders, 879-880
- Glycosaminoglycans, in clonogenic assay, 817-818
- Gold, nephrotoxicity of, 334
- Granular cell tumors, tumor markers in, 108, 156
- Granulocyte(s), function of, 650
- Granulocyte-colony-stimulating factor, in myelopoiesis, 651, 655-657
- Granulocyte-macrophage colony-stimulating factor, assay of, 812-813 in myelodysplastic syndrome treatment, 699 in myelopoiesis, 651, 655-657
- Granulocytic leukemia, chronic, mast cell leukemia in, 675
- Granulocytic sarcoma, 676, 889-901 classification of, 891 clinical features of, 890-891 cytogenetics of, 896-898 cytology/cytochemistry of, 892, 894 diagnostic approach to, 898 differential diagnosis of, 891 electron microscopy of, 895-896 epidemiology of, 890 histology of, 891-892 historical aspects of, 889-890 immunocytochemistry of, 894-895 molecular analysis of, 896-898 treatment of, 898-899
- Granulosa cell tumors, tumor markers in, 112-113
- Gross cystic disease fluid protein, as tumor marker, 68-69, 183, 186
- Growth, cellular, calcium regulation in, 540-542
- Growth factors, hematopoietic, 651, 653, 655-657 receptors for, 776-779
- Growth hormone, 473-477 adverse effects of, 476 chemical properties of, 473 in sports, 476 pharmacology of, 475 physiology of, 474-475 release of, 473
- Gunshot wounds, blood lead levels and, 444-445
- Gutzeit's test, for arsenic, 471
- Gynecologic neoplasms, tumor markers in, 105-117 cervical, 109-110 germ cell, 113-114 immunohistochemistry of, 114 ovarian, 111-114 sex cord stromal, 112-113 undifferentiated, 105-106 uterine, 110-111 vaginal, 106-109 vulvar, 106-109
- Hair, tumors of, tumor markers in, 182
- Hairy cell leukemia, markers for, 211-212
- Halogenated compounds, nephrotoxicity of, 336
- Heavy metals, nephrotoxicity of, 334-335 ototoxicity of, 345-346 toxicity of, 397-399
- Hemangioblastoma, tumor markers in, 158-159
- Hemangioma, tumor markers in, 187-188
- Hemangiopericytoma, tumor markers in, 158
- Hematocrit, in polycythemia, 858
- Hematopoiesis. See also *Myelopoiesis*. ineffective, in myelodysplastic syndromes, 685

- Hematopoietic growth factors, 651, 653, 655-657
- Hematopoietic stem cells, 650, 722-723
- Heme arginate, in myelodysplastic syndrome, 699
- Heme biosynthesis, lead effects on, 448
- Hemodialysis, aluminum toxicity in, 406-407, 410-414
in drug overdose treatment, 265-266
- Hemolysis, in arsine toxicity, 466
- Hemolysis test, of biomedical polymers, 551
- Hemoperfusion, in drug overdose treatment, 266
- Heparin, digoxin interaction with, 489
- Hepatocellular cancer, tumor markers in, 4-6, 71-72
- Hepatosplenomegaly, in myeloproliferative disorders, 827
- Her-2/*neu* (*c-erbB-2*), as tumor marker, 93-94
- HHF35 antibody, to actin, 64
- High performance liquid chromatography, cost analysis of, 596-597
in drug testing, 493
in postmortem forensic toxicology, 577-578
- Histaminase, as tumor marker, 47-48
- Histiocytoma, tumor markers in, 108
- Histiocytosis, tumor markers in, 189, 204
- HLA-DR, as tumor marker, 161
- HLA-D1 antibodies, in lymphoma diagnosis, 82
- HMB-45 antigen, as tumor marker, in malignant melanoma, 86-87
in melanocytic tumors, 86-87, 186
in vulvovaginal neoplasms, 107-108
- HMFG. See *Epithelial membrane antigen*.
- Hnk-1 antigen. See *Leu-7 antigen*.
- Hodgkin's disease, gene rearrangements in, 129-130
tumor markers in, 205-207
- Homogeneous immunoassay, cost analysis of, 598-599
- Hormones, as tumor markers, 39-45, 112-113
- Hospital information management, 239-250
Chief Information Officer in, 240-241
as new leadership option, 246-247
current positions for, 243-244
in decentralized system, 244-245
physician as, 247-248
qualifications of, 247
vs. Chief Financial Officer, 241-242
control over records in, 242
departmental systems in, 245-246
recent changes in, 240
- H222, Sp**gY* antibodies, in estrogen receptor detection, 88
- Human chorionic gonadotropin, as tumor marker, 6, 45
in germ cell neoplasms of nervous system, 174
in ovarian neoplasms, 113
in trophoblastic disease, 111
- Human growth hormone. See *Growth hormone*.
- Human immunodeficiency virus infection, blood disorders in, vs. myelodysplastic syndromes, 698
- Human milk fat globule protein. See *Epithelial membrane antigen*.
- Human papillomavirus lesions, tumor markers in, 92-93, 181-182
- Human placental lactogen, as tumor marker, 111
- Hybridization techniques. See *In situ hybridization*.
- Hydatidiform mole, tumor markers in, 111
- Hydrogen peroxide, in toxic cell injury, 313-314
- Hydroxyl radical, in toxic cell injury, 313-314
- Hydroxyurea, in polycythemia vera, 869
- Hypercalcemia, in digoxin toxicity, 483
- Hypersensitivity angitis, drug-induced, 324-325
- Hypertension, polycythemia in, 863
- Hypokalemia, in digoxin toxicity, 482-483
- Hypoxia, polycythemia in, 859-861
- Immunoassay, cost analysis of, 597-599
in drug testing, 493-494, 498, 500-501, 508-510
in postmortem forensic toxicology, 578, 585-586
- Immunocytochemistry, in granulocytic sarcoma, 894-895
- Immunofluorescence, in acute myeloid leukemia cell immunotyping, 721-722
- Immunoglobulin(s), as astrocytoma markers, 166
receptor genes in, molecular analysis of, 125-132
- Immunoglobulin G, Fc receptors for, on myeloid cell surface, 726-727
- Immunohistochemistry. See also *Monoclonal antibodies, to tumor markers*.
in nervous system tumors. See *Nervous system tumors*.
in skin tumors, 179-197
tumor markers in, 25, 59-76
cytoplasmic filaments, 61-64
diagnostic approaches in, 68-72
lineage-restricted antigens, 64-68
plastic section technique in, 199-213
- Immunophenotyping, in leukemia classification, 666-667

- Immunophenotyping (*Continued*)
 in leukemia of indeterminate lineage, 740-742
 in undifferentiated leukemia, 744, 746
 of acute myeloid leukemia cells, 721-736
 cell ontogeny and, 722-727
 methods for, 721-722
 surface antigen expression on, 727-732
- In situ hybridization, 215-245
 advantages of, 219-221
 applications of, 227-230
 basic tests in, 216-218
 commercial kits for, 227
 historical aspects of, 215-216
 nick translation labeling in, 222
 Northern blot test, 218
 probe technologies for, 216-218
 procedures for, 221
 RNA transcription in, 222-224
 sense transcript in, 223
 sensitivity of, 224-226
 Southern blot test, 218
 specificity of, 226-227
 Western blot test, 218
- Information systems. See also *Hospital information management*.
 laboratory integration and, 627-641
 for control of inputs/outputs, 628-629
 horizontal, 631-633
 market segmentation and, 638
 order-entry and, 635-637
 organization model for, 629-631
 result-reporting and, 635-637
 vertical, 633-634
 vertical quasi-, 634-635
- Instrument Cost Accounting Technique, 602-616
- Insulinoma, tumor markers in, 41-42
- Interleukin-3, in myelopoiesis, 651, 655-657
- Intermediate filaments. See *Filaments, cytoplasmic*.
- Intracutaneous test, of biomedical polymers, 552
- Intraepidermal tumors, tumor markers in, 190
- Intramuscular rabbit test, of biomedical polymers, 551-552
- Involucrin, as tumor marker, in cervical neoplasms, 109
 in epidermal tumors, 181
 in skin appendage tumors, 182
 in vulvovaginal neoplasms, 107
- Iodinated contrast media, nephrotoxicity of, 335-336
- Ion deregulation, in toxic cell injury, 531-547
- Iron, in toxic cell injury, 314
- Islet cell tumors, tumor markers in, 46-47, 54
- Isoferritins, in acute nonlymphocytic leukemia evaluation, 812
- IT protein, as tumor marker, 185
- JUN proto-oncogene, in myelopoiesis, 784
- K92 antibodies, in epithelial neoplasm diagnosis, 79
- Kanamycin, ototoxicity of, 342
- Kaposi's sarcoma, tumor markers in, 187-188
- Katacalcin, as tumor marker, 51
- Keratins, as tumor markers, in astrocytoma, 166
 in central nervous system metastases, 175
 in cervical neoplasms, 109
 in choroid plexus tumors, 159-160
 in ependymoma, 168
 in epidermal tumors, 180
 in epithelial neoplasms, 79
 in immunohistochemistry, 62-63
 in Merkel's cell carcinoma, 184
 in neuroendocrine tumors, 174
 in ovarian neoplasms, 111, 113
 in skin appendage tumors, 183-184, 186
 in uterine neoplasms, 110-111
 in vulvovaginal neoplasms, 106-108
- Keratoacanthoma, tumor markers in, 180-182
- Ki-67 antibodies, in nervous system tumor diagnosis, 151-152
- Kidney, drug excretion in, in overdose, 264
 failure of, aluminum toxicity and, 409-416
 function of, aging effects on, 486-487
 localized damage of, polycythemia and, 861
 toxic response of. See *Nephrotoxic agents*.
- KIT proto-oncogene, receptors for, 777-778
- L26 antibodies, 67
- Laboratory information systems. See *Information systems*.
- Lacto type of cancer carbohydrates, 17
- Laminin, as gliosarcoma marker, 166
- LCK proto-oncogene, in myelopoiesis, 780-781
- LE6 antibodies, in epithelial neoplasm diagnosis, 79
- Lead, 441-457
 absorption of, 445-446
 biological effects of, 448, 450-452, 454-455

- blood concentrations of, 445, 448-449
 calcium metabolism and, 446-447
 chelation therapy for, 452
 chemical properties of, 441
 excretion of, 447-448
 fetal exposure to, 449
 historical use of, 441-442
 in diet, 443
 measurement of, 447-448
 indications for, 452
 methods for, 455-456
 specimen collection for, 455-456
 nephrotoxicity of, 334
 occupational regulations concerning, 443, 449
 ototoxicity of, 346
 screening guidelines for, 453-454
 sources of, 442-445
 toxicity of, 397-398
- Legal aspects, of drug testing, liability, 527-528
 requirements, 505-506
- Leiomyoma, tumor markers in, 108, 110-111, 188
- Leiomyosarcoma, tumor markers in, 110-111, 188
- Leu-7 antigen, as tumor marker, in choroid plexus tumors, 160
 in nerve sheath tumors, 153-156
 in neuroblastoma, 170
 in oligodendroglioma, 167
 in retinoblastoma, 171
- Leu antibodies, in lymphoma diagnosis, 82
- Leu-enkephalin, as tumor marker, 44
- Leukemia. See also specific type.
 acute, lineage heterogeneity in, 676-677
 lineage switch in, 676-677
 multilineage, 676-677
 biphenotypic, 729, 747-751
 chloro-. See *Granulocytic sarcoma*.
 drug-resistant, 747
 erythro-, acute, 672-673
 thyroid hormone receptors in, 778
 granulocytic, chronic, mast cell leukemia in, 675
 hybrid type, 747-751
 in vitro assays in, 809-824
 lymphoblastic. See *Lymphoblastic leukemia*.
 lymphocytic, markers for, 211-212
 mast cell, 675-676
 megakaryoblastic, acute, 673-674
 mixed-lineage, acute, 676, 747-751
 monocytic, acute, 671-672
 myeloblastic, acute, with minimal maturation, 668
 without cytologic maturation, 667-668
 myelogenous. See *Myelogenous leukemia*.
 myeloid. See *Myeloid leukemia*.
 myelomonocytic, acute, 670-671
 chronic, 695-696, 777, 802
 nonlymphocytic. See *Nonlymphocytic leukemia*.
 of indeterminate lineage, 737-754
 acute undifferentiated, 677, 744-747
 diagnosis of, 738-743
 hybrid type, 747-751
 TdT in, 740, 742-743, 747-750
 prognosis of, assays for, 809-824
 promyelocytic, acute, 669-670
 tumor markers in, 23-25, 207-212
 undifferentiated, acute, 677, 744-747
- Leukemic colony-forming units, assays for, 809-816
- Leukocyte(s), function of, 649
- Leukocyte common antigen, as tumor marker, 106, 162-163
 in immunohistochemistry, 67
- Leukocyte function associated molecules, on myeloid cell surface, 725-726
- Leukoerythroblastosis, in agnogenic myeloid metaplasia, 832
 in myeloproliferative disorders, 826
- Levo-alpha-acetylmethadol, metabolism of, 379-381
- Lewis antigen, on myeloid cell surface, 725
- Liability, in drug testing, 527-528
- Light chains, as lymphoma markers, 203
- Light microscopy, in leukemia of indeterminate lineage, 738-739
- Lineage-restricted antigens, as tumor markers, 64-68. See also specific marker, e.g., *Carcinoembryonic antigen*.
- Lipid peroxidation, in toxic cell injury, 316-317
- Liquid culture systems, in myeloproliferative disorders, 817-818
- Lithium, nephrotoxicity of, 335
- Liver, cancer of, tumor markers in, 4-6, 71-72
 drug metabolism in, in overdose, 263
 function of, aging effects on, 496
 sampling of, for postmortem toxicology testing, 574
- Loop diuretics, nephrotoxicity of, 333
 ototoxicity of, 344-345
- Lung neoplasia, tumor markers in, 84-86
- Lymphoblastic leukemia, acute, Philadelphia chromosome in, 846-847, 850-852
 ras gene mutation in, 801
 surface antigens in, 729
 TdT enzyme in, 740
 vs. acute myeloid leukemia, 737-743
 chronic, *ras* gene mutation in, 801
- Lymphocyte(s), function of, 650
- Lymphocytic leukemia, acute, markers for, 211
 chronic, markers for, 211-212

- Lymphoid neoplasms, molecular analysis of, 119-149
 cytogenetics of, 133-134
 DNA digestion in, 143-144
 DNA isolation in, 140-143
 genetic rearrangements detected by, 126-132
 immunoglobulin gene probes in, 125-130
 immunoglobulin gene structure in, 120-123
 pitfalls in, 130-133
 polymerase chain reaction technique in, 135
 pulse-field gel electrophoresis in, 135-136
 Southern blot test, 145-149
 T cell receptor gene probes in, 125-130
 T cell receptor gene structure in, 124
 tumor markers in, 23-25
 immunohistochemical techniques and, 199-213
- Lymphoma, tumor markers in, 23-25
 gene translocations, 27
 in immunohistochemistry, 67-68
 in undifferentiated neoplasm, 68, 71-72
 monoclonal antibodies to, 81-82, 86
 nervous system, 161-163
 non-Hodgkin's, 202-204
 vulvovaginal, 108
 vs. granulocytic sarcoma, 892, 898
- Lysozyme, in granulocytic sarcoma diagnosis, 894
- Mac 387, as leukemia marker, 208
- Macrophage-colony-stimulating factor, in myelopoiesis, 651, 655-657, 776-777
- Major histocompatibility complex antigens, as astrocytoma markers, 166
- Malignant histiocytosis, tumor markers in, 204
- Malignant melanoma, tumor markers in, 21, 23, 186
 in undifferentiated neoplasm, 68, 71
 monoclonal antibody detection of, 86-87
 vulvovaginal, 107-108
- Marijuana, determination of, in urine, 301-308
- Marsh's test, for arsenic, 470
- Mass spectrometry. *See also Gas chromatography/mass spectrometry.*
 cost analysis of, 599
 in drug testing, 493, 495, 497-498, 508-510
- Mast cell leukemia, acute, 675
- MB series antibodies, 67-68
- MBr1 antibodies, in epithelial neoplasm diagnosis, 80
- MDR proto-oncogene, in myeloproliferative disease, 789
- ME1 and ME 2 antibodies, in mesothelioma diagnosis, 81
- Medical examiners' system. *See Forensic toxicology, postmortem.*
- Medical records management. *See Hospital information management.*
- Medical review officer, in drug testing program, 522-529
- Medulloblastoma, tumor markers in, 172-173
- Megakaryoblast(s), electron microscopy of, 896
- Megakaryoblastic leukemia, acute, 673-674
- Megakaryocytes, abnormalities of. *See also Dysmegakaryocytopoiesis.*
 platelet abnormalities in, 873-874, 877
- Melanocytic tumors. *See also Malignant melanoma.*
 tumor markers in, 186
- Meningeal carcinomatosis, tumor markers in, 175
- Meningioma, tumor markers in, 156-158
- Mercury, nephrotoxicity of, 334
 ototoxicity of, 346
 toxicity of, 398-399
- Merkel cell carcinoma, tumor markers in, 108, 184-185
- Mesenchymal neoplasms, tumor markers in, 108, 187-188
- Mesothelioma, tumor markers in, 72, 81
- Metabolism, mitochondrial, in toxic cell injury, 318-319
 of alcohol, 369-371
 of drugs, for opiate dependency treatment, 375-386
 in overdose, 263, 265
- Metals, nephrotoxicity of, 334-335
 ototoxicity of, 345-346
 toxicity of, 397-399
- Metastasis, tumor markers in, cutaneous, 190
 in germ cell neoplasms of nervous system, 175
 monoclonal antibody detection of, 81, 86-87
 ovarian, 114
 vulvovaginal, 108
- Methacrylate plastics, in immunohistochemistry, 200
- Methadone, metabolism of, 375-379
 monitoring of, 378-379
- Methamphetamines, determination of, in urine, 301-308
- Methicillin, nephrotoxicity of, 325
- Microscopy. *See also Electron microscopy.*

- digital imaging fluorescence, in toxic cell injury study, 531-547
- in leukemia of indeterminant lineage, 738-739
- Microtubule-associated proteins, as neuroblastoma markers, 170
- Minocycline, ototoxicity of, 347
- Mitochondrial metabolism, in toxic cell injury, 318-319
- Molecular analysis, in lymphoid neoplasms. See under *Lymphoid neoplasms*.
- of granulocytic sarcoma, 896-898
- Monoclonal antibodies. See also *Immunohistochemistry*.
- hybridization techniques and, 229-230
- in acute myeloid leukemia treatment, 731-732
- in breast carcinoma, 88
- in flow cytometry, 94
- in granulocytic sarcoma diagnosis, 894-895
- in leukemia classification, 666-667
- in lung neoplasia, 84-86
- in lymphoma, 81-82
- in mesothelioma, 81
- in metastatic adenocarcinoma, 81
- in metastatic malignant melanoma, 86-87
- in small cell undifferentiated neoplasms, 87
- to capsid antigen, 92-93
- to epithelial cells, 79-80
- to estrogen receptors, 88-89
- to fetal brain cells, 89-90
- to glial fibrillary acidic protein, 90-92
- to intermediate filaments, 87, 91
- to oncogenes, 93-94
- to proto-oncogenes, 93-94
- to S100, 91
- to tumor markers, 9-17, 77-103
- cell transformation and, 93-94
- in cerebrospinal fluid, 89-92
- in cervical smears, 92-93
- in fine needle aspiration biopsy specimens, 83-89
- in peritoneal washings, 82-83
- in serous effusions, 78-82
- Monocytes, function of, 649-650
- Monocytic leukemia, acute, 671-672
- Morphine, postmortem testing for, 585
- Morton's neuroma, tumor markers in, 156
- MOv2 antibodies, in epithelial neoplasm diagnosis, 80
- MPO-7, as leukemia marker, 208
- Mucin cancer antigen, as tumor marker, 15
- Multiple endocrine neoplasia syndromes, tumor markers in, 49-55
- Multiple myeloma, tumor markers in, 1-2
- Multipotential stem cells, in myelopoiesis, 650
- Muramidase, in granulocytic sarcoma diagnosis, 894
- Muscle, growth hormone effects on, 474
- Mutagenesis, calcium regulation in, 541-542
- of biomedical polymers, assay of, 552-553, 559, 562
- Mutation, of *ras* genes, in myeloproliferative disorders, 797-807
- myb oncogene, in myelopoiesis, 784
- MYB proto-oncogene, in myelopoiesis, 784-785
- myc oncogene, as tumor marker, 30
- Myelin basic protein, as tumor marker, 108, 154-156, 167
- Myeloblast(s), electron microscopy of, 895-896
- increased, in myelodysplastic syndromes, 686-687
- Myeloblastic leukemia, acute, with minimal maturation, 668
- without cytologic maturation, 667-668
- Myeloblastoma. See *Granulocytic sarcoma*.
- Myelocytic leukemia, chronic, granulocytic sarcoma in, 890
- Myelocytoma. See *Granulocytic sarcoma*.
- Myelodysplastic syndromes, 683-705
- bone marrow abnormalities in, 688-689
- cell culture abnormalities in, 688-689
- chromosomal abnormalities in, 684, 688, 755-767
- proto-oncogenes and, 786-789
- chronic myelomonocytic leukemia as, 694-695
- classification of, 689-698, 804
- clinical features of, 684-685
- clonogenic assays in, 812
- de novo*, chromosomal abnormalities in, 758-759
- diagnostic features of, 685-688
- differential diagnosis of, 698-699
- etiology of, 684
- growth factors in, 775-776
- pathogenesis of, 684
- prognosis of, 700-701
- progression to acute myeloid leukemia, 677
- ras* gene mutation in, 799-800, 802-804
- refractory anemia as, 689-694
- secondary, 696-697, 764
- treatment of, 699-700
- trilineage dysplasia in, 677-678
- unclassified, 697-698
- Myelofibrosis with myeloid metaplasia, colony-stimulating factors in, 813
- Myelogenous leukemia, chronic, acute transformation of, 816, 831
- colony-stimulating factors in, 813
- laboratory findings in, 827-831
- Philadelphia chromosome absent in, 845-846

- Myelogenous leukemia (*Continued*)
 Philadelphia chromosome in, 840, 842-846, 850-852
 platelet disorders in, 873, 876, 878
 prognosis of, 844-845
ras gene mutation in, 801
- Myeloid leukemia, acute, biphenotypic, 729
 cell differentiation in, antigenic modulation in, 727
 cell ontogeny in, 722-727
 chromosomal abnormalities in, 755-767, 777
 proto-oncogenes and, 786-789
 classification of, 661-681
 M0 to M7 types, 667-674
 reproducibility of, 674-675
 cytochemistry of, 664-666, 707-720
de novo, chromosomal abnormalities in, 759-763
 erythroid cell count in, 662
 erythroleukemia (M6), 672-673, 778
 granulocytic sarcoma in, 676, 890-891, 896, 898
 growth factors in, 775
 immunophenotyping in, 666-667, 721-736
 lineage heterogeneity in, 676-677
 markers for, 208-211
 megakaryoblastic (M7), 673-674
 mixed lineage, 729
 molecular biology of, 769-796
 growth factor receptors in, 776-779
 normal myelopoiesis and, 769-776
 nuclear proteins in, 783-786
 recurrent chromosomal rearrangements in, 786-790
 signal transducers in, 779-783
 transcription factors in, 783-786
 monocytic (M5a and M5b), 671-672
 myeloblastic, with minimal maturation (M1), 668
 without cytologic maturation (M0), 667-668
 myelodysplastic syndromes preceding, 700
 myelomonocytic (M4), 670-671
 myelomonocytic with eosinophilia (M4-Eo), 671
 progenitor cells in, 729-730
 prognosis of, antigen expression and, 730-732
 promyelocytic (M3), 669-670
ras genes in, 797-807
 secondary, chromosomal abnormalities in, 764-765
 surface antigen expression in, 727-732
 TdT enzyme in, 740
 treatment of, antigen expression considerations in, 730-732
 undifferentiated, 677
 vs. acute lymphoblastic leukemia, 737-743
 vs. myelodysplastic syndromes, 683, 698
 with significant maturation (M2), 668-669
 with trilineage dysplasia, 677-678
 chronic, cytochemistry of, 707-720
 Myeloma paraproteins, as tumor markers, 1-2
 Myelomonocytic leukemia, acute, 670-671
 with eosinophilia, 671
 chronic, 695-696
 chromosomal abnormalities in, 777
 ras gene mutation in, 802
 Myeloperoxidase, in leukemia classification, 664-665, 739
 Myelopoiesis, 649-659, 722-727. See also *Hematopoiesis*.
 bone marrow microenvironment in, 653, 655
 cell types and, 649-650
 committed progenitor cells in, 651
 growth factors in, 655-657, 773-776
 proto-oncogenes in. See *Proto-oncogenes, in myeloid cells*.
 stem cells in, 650-651
 suppressor genes in, 773-776
 Myeloproliferative disorders. See also specific disorder, e.g., *Leukemia; Myelodysplastic syndromes*.
 acute, 825-826
 chromosomal abnormalities in, 753-767
 chronic. See also specific disorder.
 classification of, 825-838
 diagnostic features of, 826-827
 granulocyte-macrophage colony-stimulating factor assay in, 812-813
 transitions among, 827
 diagnosis of, cytochemical procedures in, 707-720
 granulocytic sarcoma, 676, 889-901
 immunophenotyping in, 721-736
 leukemic cell studies in, 809-824
 myeloid metaplasia, agnogenic, 825-838
 myelopoiesis biology and, 649-659
 Philadelphia chromosome detection in, 839-855
 platelet abnormalities in, 873-888
 polycythemic, 857-871
 ras gene mutations in, 797-807
 Myogenic neoplasms, tumor markers in, 108
 Myoglobin, as tumor marker, 108
 Myosin, in immunohistochemistry, 64
- Naltrexone, metabolism of, 383
 Naphthol AS acetate, in myeloid leukemia
 diagnosis/treatment, 711

- Naphthol ASD acetate, in leukemia classification, 665, 711
- Naphthol ASD chloroacetate, in leukemia classification, 665, 712-713
- α -Naphthyl acetate, in myeloid leukemia diagnosis/treatment, 711
- α -Naphthyl butyrate, in myeloid leukemia diagnosis/treatment, 711
- National Institute on Drug Abuse, testing guidelines of, 496-497, 503-504, 518-520
- on medical review officer qualifications, 523-524
- Needle aspiration biopsy specimens, tumor markers in, 83-89
- Neomycin, ototoxicity of, 342
- Neoplasia, calcium regulation in, 540-542
- Nephrotoxic agents, 323-338
- action of, 323-324
- acute tubular necrosis from, 326
- analgesics, 337-338
- antimicrobial agents, 329-332
- antineoplastic drugs, 332-333
- captopril, 336
- cimetidine, 332
- diuretics, 333
- drugs of abuse, 333
- effects on elderly persons, 324
- glomerular changes from, 326-336
- halogenated compounds, 336
- heavy metals, 334-335
- interstitial nephropathy from, 336-337
- nonsteroidal anti-inflammatory drugs, 335
- organic solvents, 336
- papillary nephropathy from, 336-338
- radioiodinated contrast media, 335-336
- vascular changes from, 324-326
- Nerve sheath tumors, tumor markers in, 153-156
- Nervous system tumors, inflammatory reactions in, vs. lymphoma, 163-164
- tumor markers in, 151-178
- antigen expression and, 152-153
- chordoma, 174
- choroid plexus, 159-160
- germ cell, 174-175
- glial cell, 164-168
- hemangioblastoma, 158-159
- lymphoid, 161-164
- meningioma, 156-158
- metastatic, 175
- nerve sheath, 153-156
- neuroendocrine, 173-174
- of skin, 187
- primitive neuroectodermal, 168-173
- neu(c-erb B-2)* oncogene, as tumor marker, 30-31
- Neuroblastoma, tumor markers in, 47, 168-171
- Neuroendocrine tumors, tumor markers in, 173-174
- Neurofibroma, tumor markers in, 108, 155
- Neurofibrosarcoma, tumor markers in, 155
- Neurofilament protein, as tumor marker, 113
- in immunohistochemistry, 64
- in medulloblastoma, 172
- in neuroblastoma, 168, 170
- Neurogenic neoplasms, tumor markers in, 66-67, 108
- Neuroma, tumor markers in, 108, 156
- Neurometrics, in neurotoxic exposure, 396-397
- Neuron-specific enolase, as tumor marker, 47
- in astrocytoma, 166
- in cervical neoplasms, 110
- in choroid plexus tumors, 160
- in immunohistochemistry, 67-68
- in medulloblastoma, 172
- in nervous system tumors, 152-153
- in neuroblastoma, 170
- in neuroendocrine tumors, 173
- in ovarian neoplasms, 113
- in retinoblastoma, 171
- in uterine neoplasms, 110
- in vulvovaginal neoplasms, 108
- Neurotoxicant exposure, 387-402
- clinical evaluation in, 388-397
- heavy metals, 397-399
- pesticides, 399-401
- volatile inhalants, 399
- Neutrophils, abnormal, in myelodysplastic syndromes, 688
- Nevi, tumor markers in, 186
- Nitrogen mustard, ototoxicity of, 343
- NK 1 C3 antigen, as tumor marker, 186
- NK1 antibodies, in malignant melanoma diagnosis, 86
- Non-Hodgkin's lymphoma, tumor markers in, 202-204
- Nonlymphocytic leukemia, acute, clonogenic assays in, 810-812
- polycythemia vera and, 868-869
- treatment response in, 813-820
- Nonspecific esterases, in leukemia classification, 665
- in myeloid leukemia diagnosis/treatment, 710-712
- Nonsteroidal anti-inflammatory drugs, nephrotoxicity of, 335
- Northern blot test, 218
- Nuclear proteins, in myelopoiesis, 783-786
- Nuclear Regulatory Commission, drug testing program of, 520
- Nucleic acid probes. *See In situ hybridization.*
- Oat cell carcinoma, tumor markers in, 46

- Occupational exposure, to arsenic, 462
to lead, 443, 455
- OKT-9, as neuroblastoma marker, 170
- Oligodendroglioma, tumor markers in, 167-168
- Oncodevelopmental tumor markers, 2-3, 48-49. See also specific marker, e.g., *Alpha-fetoprotein*.
- Oncogenes, as tumor markers, 27-31
c-erbB-2 (neu), 30-31, 93-94
hybridization techniques in, 229
monoclonal antibody detection of, 93-94
myc, 30
neu(c-erb B-2), 30-31
ras, 28, 30
in myelodysplastic syndromes, *ras*, 684
in myelopoiesis, v-myb, 784
in myeloproliferative disorders, v-erb, 778
v-fms, 777
- Opiates, dependency on, treatment of, 375-386
buprenorphine in, 381-382
clonidine in, 382-383
levo-alpha-acetylmethadol in, 379-381
methadone in, 375-379
naltrexone in, 383
urine testing for, 493, 496-498, 500
- Opsin, as medulloblastoma marker, 172
- Organic solvents, nephrotoxicity of, 336
- Organophosphate pesticides, toxicity of, 399-400
- Osteodystrophy, in dialysis, 411-415, 423-426
- Osteomalacia, in dialysis, 412-414, 423-426
- Ototoxic agents, 338-347
action of, 338
aminoglycosides, 339-343
analgesics, 345-346
antibiotics, 347
antineoplastic drugs, 343-344
antipyretics, 345-346
chemicals, 346
chloroquine, 346
cochlear hair cell injury damage from, 339-344
diuretics, 344-345
heavy metals, 345-346
quinine, 346
stria vascularis damage from, 344-345
vestibular neuroepithelial damage from, 339-344
- Ovarian neoplasms, tumor markers in, 111-114
- Oxidative stress, in toxic cell injury, 539-540
- Oxygen, activated, in toxic cell injury, 313-315
- P53 nuclear protein, in myelopoiesis, 784-785
- Paget's disease, tumor markers in, 107, 185-186
- PAI proto-oncogene, in myeloproliferative disease, 789
- Pancreastatin, as tumor marker, 46
- Pancreatic polypeptide, as tumor marker, 41, 54
- Pancreatic tumors, tumor markers in, 41-43, 54
- Pancytopenia, in agnogenic myeloid metaplasia, 832
in myelodysplastic syndromes, 685
- Paraganglioma, tumor markers in, 174
- Parathyroid gland tumors, tumor markers in, 46, 53-55
- Parathyroid hormone, in aluminum-induced bone disease, 414, 424
- PCP (phencyclidine), urine testing for, 301-308, 493, 496-497, 500
- Peanut lectin, as epidermal tumor marker, 181
- Penicillamine, in arsenic poisoning, 470
- Penicillins, nephrotoxicity of, 330
- Pentagastrin stimulation test, in multiple endocrine neoplasia syndrome, 49-51
- Periodic acid-Schiff reaction, in leukemia classification, 665, 713-714
- Peritoneal washings, tumor markers in, 82-83
- Peroxidases, in myeloid leukemia diagnosis/treatment, 707-709
- Peroxidation, of lipids, in toxic cell injury, 316-317
- Personnel performance, in drug testing, 506-508
- Pesticides, toxicity of, 399-401
clinical evaluation in, 388-397
- Pharmacokinetics, of buprenorphine, 381-382
of clonidine, 382-383
of drug overdose, 261-269
absorption in, 261-262, 264-265
antidotes and, 266
distribution in, 262-263
excretion in, 264-266
metabolism in, 263, 265
serum concentrations and, 267-268
of levo-alpha-acetylmethadol, 379-381
of methadone, 375-379
of naltrexone, 383
- Phenacetin, nephrotoxicity of, 337-338
- Phencyclidine, urine testing for, 301-308, 493, 496-497, 500
- Pheochromocytoma, tumor markers in, 46, 49, 52, 174
- Philadelphia chromosome, as tumor marker, 26
detection of, 839-855

- bcx test for, 842-845
- in residual disease, 852
- polymerase chain reaction in, 848-852
- pulsed-field gel electrophoresis in, 846-847
- in acute lymphoblastic leukemia, 846-847, 850-852
- in chronic myelogenous leukemia, 830-831, 840, 842-846, 850-852
- in granulocytic sarcoma, 897
- molecular biology of, 839-842
- Phlebotomy, in polycythemia vera, 866
- Phosphate-binding agents, aluminum in, 405-406
- Phospholipases, in toxic cell injury, 317-318
- Phospholipids, catabolism of, in toxic cell injury, 316-318
- Phosphorus, radioactive, in polycythemia vera, 866
- Photometer, in platelet aggregation testing, 880-882
- Pilocytic astrocytoma, tumor markers in, 166
- Pilomatricoma, tumor markers in, 182
- PIM-1 proto-oncogene, in myelopoiesis, 782
- Pineocytoma, tumor markers in, 173
- Pituitary adenoma, tumor markers in, 40, 43, 54-55
- Placental alkaline phosphatase, as tumor marker, 113
- Plasma volume, in polycythemia, 858
- Plastic section immunohistochemistry, in lymphoid tumors, 199-213
- Platelet(s), function of, 649
 - in myeloproliferative disorders, 829-830, 873-888
 - aggregation of, 880-882
 - density of, 876-877
 - disorders of, 826
 - function of, 880-882
 - glass bead adhesion test of, 880
 - glycoproteins in, 879-880
 - number of, 874
 - secretory granular content of, 877-879
 - size/size distribution of, 875-876
 - survival of, 875
 - ultrastructural morphology of, 876-877
- Platelet factor 4, in myeloproliferative disorders, 879
- Platelet peroxidase, in leukemia classification, 666
- Pleural effusions, monoclonal antibody studies of, 78-82
- Poisoning. See *Toxicology*.
- Poly(anhydrides), toxicology/biocompatibility testing of, 556-566
- Poly[bis(p-carboxyphenoxy)] propane, toxicology/biocompatibility testing of, 557-559, 562-566
- Poly[bis(p-carboxyphenoxy)] propane-sebacic acid, toxicology/biocompatibility testing of, 559, 562-566
- Polycythemia, 857-871
 - absolute, appropriate, 859-861
 - familial, 862
 - in autotransfusion, 862
 - inappropriate, 861
 - polycythemia vera, 863-869, 873-874, 876-878
 - definition of, 858
 - differential diagnosis of, 858-863
 - hematocrit in, 858
 - pathophysiology of, 858-863
 - plasma volume in, 858
 - primary (polycythemia vera), 863-869, 873-874, 876-878
 - red blood cell mass in, 858
 - relative, 862-863
- Polycythemia vera, 863-869
 - platelet disorders in, 873-874, 876-878
- Polymerase chain reactions, as tumor markers, 31-32, 135
 - in granulocytic sarcoma, 897
 - in leukemia, 848-852
 - in *ras* gene detection, 798
- Polymers, biomedical, biocompatibility/toxicology of, 549-570
- Polymyxin-B, nephrotoxicity of, 331
- Polyurethanes, toxicology/biocompatibility testing of, 557-559
- Postmortem forensic toxicology. See *Forensic toxicology*.
- Pregnancy-specific beta-1-glycoprotein, as tumor marker, 174
- Primitive neuroectodermal tumors, tumor markers in, 168, 170
- Proficiency testing, in drug testing laboratory, 510-513, 529
- Progenitor cells, committed, in myelopoiesis, 651, 723
 - in acute myeloid leukemia, 729-730
 - leukemic, assays of, 809-810
- Pregnane receptor proteins, in immunohistochemistry, 66
- Prolactin, as tumor marker, 40
- Promyelocytic leukemia, acute, 669-670
- Prostate-specific antigen, as tumor marker, 15
 - in immunohistochemistry, 66
- Protein thiols, in toxic cell injury, 315-316
- Proto-oncogenes, as tumor markers, 27-31, 93-94
 - in myeloid cells, 769-796
 - growth factor receptors in, 776-779
 - in myeloproliferative disease, 786-790
 - normal, 769-776
 - nuclear proteins in, 783-786
 - signal transducers in, 779-783
 - transcription factors in, 783-786

- Psychometrics, in neurotoxic exposure, 396
- Pulsed-field gel electrophoresis, in lymphoid neoplasms, 135-136
- in Philadelphia chromosome detection, 846-847
- Quality assurance, in drug testing, 499, 503-516
- adulterated specimens in, 514
- certification in, 513-514
- laboratory certifying official in, 506-507, 509-510
- legal requirements of, 505-506
- personnel impact on, 506-508
- procedures for, 508-510
- proficiency testing in, 510-513, 529
- sample collection in, 504-505
- security in, 505
- standard operating procedures and, 505-506, 509-510
- information systems in. *See Information systems.*
- Quinidine, digoxin interaction with, 488
- Quinine, ototoxicity of, 346
- Radioimmunoassay, cost analysis of, 597-598
- in drug testing, 493
- Radiotherapy, myelodysplastic syndromes in, 695-696
- ras* genes, as tumor marker, 28, 30
- mutations of, in myeloproliferative disorders, 684, 797-807
- clinical outcome and, 803-804
- detection methods for, 798
- in sustaining leukemic phenotype, 801-802
- nature of, 803
- prevalence of, 799
- timing of, 799-800
- vs. type of leukemia, 801-802
- RAS proto-oncogene, in myelopoiesis, 782-783
- Reactive thrombocytosis, platelet disorders in, 874
- Receptor proteins, as tumor markers, in immunohistochemistry, 66
- in meningioma, 158
- in ovarian neoplasms, 114
- monoclonal antibody detection of, 88-89
- Red blood cell mass, in polycythemia, 858
- Reed-Sternberg cells, in Hodgkin's disease, 203-205
- Refractory anemia, chromosomal abnormalities in, 759
- in myelodysplastic syndromes, 686, 689-694
- with excess blasts, 693-694
- with excess blasts in transformation, 694-695
- with ringed sideroblasts, 690-691
- Reinsch's method, for arsenic, 471
- Retinoblastoma, tumor markers in, 171-172
- Retinoblastoma suppressor gene, in myelopoiesis, 785-786
- Rhabdomyosarcoma, tumor markers in, 65-66, 108
- Rhodopsin, as retinoblastoma marker, 171
- Rifampicin, nephrotoxicity of, 331
- Rifampin, digoxin biotransformation and, 486
- Ringed sideroblasts, in myelodysplastic syndromes, 686, 690-691
- RNA hybridization. *See In situ hybridization.*
- RNA polymerase chain reactions, as tumor markers, 31-32
- S-antigen, as tumor marker, in medulloblastoma, 172
- in pineocytoma, 173
- in retinoblastoma, 171
- S100 protein, as tumor marker, in astrocytoma, 166
- in cerebrospinal fluid studies, 91
- in choroid plexus tumors, 160
- in immunohistochemistry, 66-67
- in melanocytic tumors, 86-87, 186
- in meningioma, 156
- in nerve sheath tumors, 153-156
- in neuroblastoma, 170
- in neuroendocrine tumors, 173
- in oligodendroglioma, 167
- in skin tumors, 187
- in sweat gland tumors, 183
- in vulvovaginal neoplasms, 106-108
- monoclonal antibodies to, 86-87, 91
- S100 protein beta-polypeptide, as ependymoma marker, 168
- Salicylates, nephrotoxicity of, 337-338
- ototoxicity of, 345-346
- Sarcoma, granulocytic, 676, 889-901
- tumor markers in, in undifferentiated neoplasm, 68, 71-72
- Sarcoma botryoides, tumor markers in, 108
- Schwannoma, tumor markers in, 108, 154-155
- Screening, for drugs-of-abuse, 493-502
- for lead, 453-454
- Sebaceous gland tumors, tumor markers in, 184
- Secretin stimulation test, in gastrinoma, 54
- Secretogranins, as tumor markers, 45-46

- Security, in drug testing laboratory, 505
- Self-renewal assay, in myeloproliferative disorders, 813-817
- Seminoma, tumor markers for, 6
- Sensitization testing, of biomedical polymers, 554, 556
- Serine kinase, in myelopoiesis, 782
- Serotonin deficiency, in platelets, in myeloproliferative disorders, 878-879
- Serous effusions, monoclonal antibody studies of, 78-82
- Sertoli-Leydig cell tumors, tumor markers in, 112-113
- Sex cord stromal tumors, tumor markers in, 112-113
- Sideroblasts, ringed, in myelodysplastic syndromes, 686, 690-691
- Signal transducers, in myelopoiesis, 779-783
- Siipple's syndrome, tumor markers in, 49-53
- Skin tumors, tumor markers in, 179-197
- appendage, 182-186
 - epidermal, 180-182
 - fibrous, 188
 - histiocytic, 189
 - intraepidermal malignancy, 190
 - melanocytic, 186
 - mesenchymal, 187-188
 - metastatic, 190
 - neural, 187
 - poorly differentiated, 189-190
 - small epithelioid malignancy, 190
 - smooth muscle, 188
 - spindle cell, 190
 - vascular, 187-188
 - vulvovaginal carcinoma of, 108
- Small cell carcinoma, tumor markers in, 46-47
- Small cell undifferentiated neoplasms, tumor markers in, monoclonal antibody detection of, 87
- Small epithelioid tumors, tumor markers in, 190
- Smoking, polycythemia in, 860, 862
- Software, for information systems. *See Information systems.*
- Somatostatin, as tumor marker, 51
- Southern blot test, 145-149, 218
- in leukemia diagnosis, 842-844
- Specimen collection, for postmortem toxicology testing, 573-575
- Spectrometry, atomic absorption, in aluminum determination, 427-432
- mass. *See Gas chromatography/mass spectrometry.*
- Spectrophotometry, cost analysis of, 592, 594
- in arsenic analysis, 470-471
 - in postmortem forensic toxicology, 576
- Spindle cell tumors, tumor markers in, 190
- Sports, growth hormone use/abuse in, 476
- Spot tests, cost analysis of, 592, 594
- Squamous cell carcinoma, tumor markers in, in cervical neoplasms, 109
- in epidermal tumors, 180-181
 - vulvovaginal, 106-107
- Squamous epithelial lesions, cervical, tumor markers in, 109-110
- SRC proto-oncogene, in myelopoiesis, 779-781
- Stem cells, hematopoietic, in myelopoiesis, 650
- Steroid receptor proteins, as tumor markers, in immunohistochemistry, 66
- in meningioma, 158
 - in ovarian neoplasms, 114
 - monoclonal antibody detection of, 88-89
- Stomach contents, for postmortem toxicology testing, 574
- Storage pool deficiency, in myeloproliferative disorders, 877-879
- Streptomycin, ototoxicity of, 341-342
- Substance P, as retinoblastoma marker, 171
- Sudan Black B, in leukemia classification, 664-665, 709-710
- Sulfonamides, nephrotoxicity of, 330-331
- Superoxides, in toxic cell injury, 313-314
- Supplemental Appropriations Act, on drug testing, 518
- Sweat gland tumors, tumor markers in, 183-184
- Synaptophysin, as tumor marker, in immunohistochemistry, 67
- in medulloblastoma, 172
 - in neuroblastoma, 170
 - in neuroendocrine tumors, 173
 - in retinoblastoma, 171
- T cell(s), development of, 124-125
- T cell markers, in lymphoma, 202-204
- T cell neoplasms, gene rearrangements in, 129
- tumor markers in, 23-25
- TAG. *See Tumor-associated glycoprotein.*
- Taq polymerase, in Philadelphia chromosome detection, 848, 850
- TdT (terminal deoxynucleotidyl transferase), as leukemia marker, 208-211
- in leukemia of indeterminant lineage, 740, 742-743, 747-750
- Teratogenicity assay, of biomedical polymers, 553, 562
- Teratoma, tumor markers in, 113-114
- Terminal deoxynucleotidyl transferase (TdT), as leukemia marker, 208-211
- in leukemia of indeterminant lineage, 740, 742-743, 747-750
- Tetracycline, nephrotoxicity of, 331-332

- Tetrazolium salts, in leukemic cell assay, 818
- Thin layer chromatography, cost analysis of, 597
- in drug testing, 493, 496, 501
- Threonine kinase, in myelopoiesis, 782
- Thrombocytopenia, essential, platelet disorders in, 873-874, 876-878
- Thrombocytopenia, in agnogenic myeloid metaplasia, 832
- Thrombocytosis, reactive, platelet disorders in, 874
- β -Thromboglobulin, in myeloproliferative disorders, 879
- Thrombosis, in polycythemia vera, 866-867
- Thyroglobulin, as tumor marker, 41, 114
- Thyroid cancer, tumor markers in, 41, 48-51
- Thyroid hormone receptor, in myelopoiesis, 778-779
- Tissue culture-agar overlay test, of biomedical polymers, 550-551
- Tissue polypeptide antigen, as tumor marker, 16-17, 109
- Tobramycin, ototoxicity of, 342
- Toluidine blue, in myeloid leukemia diagnosis/treatment, 716
- Toxicology. *See also Drug abuse.*
- cell injury mechanisms and, 311-321
- calcium regulation and, 531-547
- laboratory cost analysis in, 591-623
- of alcohol, 355-374
- of aluminum, 403-422
- quantification of, 423-433
- of arsenic, 459-472
- of biomedical polymers, 549-570
- of digoxin, in elderly patient, 479-492
- of drug overdose, 261-269
- of human growth hormone, 473-477
- of lead, 441-457
- of nephrotoxic agents, 323-338
- of neurotoxins, 387-402
- of opiate detoxification drugs, 375-386
- of ototoxic agents, 338-347
- pharmacokinetics and, 261-269
- postmortem forensic, 571-589
- urine testing and, detection rates in, 289-299
- gas chromatography/mass spectrometry in, 271-288
- quantitative levels for, 301-309
- Transcription factors, in myelopoiesis, 783-786
- Transfection assay, in *ras* gene detection, 798
- Transferrin, as aluminum binder, 408
- as neuroblastoma marker, 170
- Trichilemmoma, tumor markers in, 182
- Trichoepithelioma, tumor markers in, 182
- Trichofolliculoma, tumor markers in, 182
- Trophoblastic disease, gestational, tumor markers in, 111
- Tropomyosin, as tumor marker, in immunohistochemistry, 64
- Tubular necrosis, from nephrotoxic agents, 327
- Tubulin, as neuroblastoma marker, 170
- Tumor(s), polycythemia and, 861
- promotion of, calcium regulation in, 542
- Tumor angiogenic factor, in biomedical polymer testing, 556-557
- Tumor-associated glycoprotein (TAG-72), as tumor marker, 16
- antibodies to, 80
- in lung neoplasia, 84
- in uterine neoplasms, 110
- monoclonal antibody detection of, 84
- Tumor markers. *See also specific diseases and marker.*
- alpha-fetoprotein. *See Alpha-fetoprotein.*
- antibodies to. *See Antibodies; Monoclonal antibodies.*
- Bence-Jones protein, 1-2
- CA 15-3/19-9/50/125, 15-16
- carbohydrates, 17
- carcinoembryonic antigen. *See Carcinoembryonic antigen.*
- chromogranins, 45-46, 67, 108, 110, 113
- combined use of, 17, 21
- commercialization of, 23
- early discoveries of, 1-2
- ectopic vs. eutopic hormones as, 43-45
- enzymes, 47-48
- gene amplifications in, 27
- gene translocations in, 27
- genetic, 26
- history of, 3-32
- hormones, 39-45, 112-113
- human chorionic gonadotropin, 6, 45, 111, 113, 174
- hybridization techniques and, 229
- immunohistology and, 25
- in cerebrospinal fluid, 89-92
- in cervical smears, 92-93
- in endocrine malignancies, 39-57
- in fine needle aspiration biopsy specimens, 83-89
- in gynecologic neoplasms, 105-117
- in immunohistochemistry, 59-76
- cytoplasmic filaments, 61-64
- diagnostic approaches in, 68-72
- lineage-restricted antigens, 64-68
- plastic section technique in, 199-213
- in lymphoid neoplasms, 161-164, 199-213
- in nervous system neoplasms, 151-178
- in peritoneal washings, 82-83
- in serous effusions, 78-82
- in skin tumors, 179-197
- in stimulation tests, 40-41
- in suppression tests, 40-41

- in undifferentiated neoplasms, 59-76
 diagnostic approaches in, 68-72
 lineage-restricted antigens, 64-68
 leukocyte common antigen, 67, 106, 162-163
 lymphoid, 23-25, 119-149
 melanoma-associated, 21, 23
 monoclonal antibodies to. See under *Monoclonal antibodies*.
 mucin cancer antigen, 15
 myeloma paraproteins, 1-2
 oncodevelopmental antigens, 48-49
 oncodevelopmental nature of, 2-3
 polymerase chain reactions in, 31-32, 66
 prostate-specific antigen, 15
 proto-oncogenes, 27-31
 review of, 1-37
 sensitivity of, 11
 specificity of, 11, 15
 TAG-72, 16, 80, 84, 110
 test kits for, 23
 tissue polypeptide antigen, 16-17
 types of, 2-3
Tumor suppressor genes, 771
Tyrosine kinases, in myelopoiesis, 779-782
 RAS proto-oncogenes and, 783

UEA lectins. See *Ulex europaeus agglutinin lectins*.
UJ13A antibodies, in cerebrospinal fluid studies, 89
UJ127.11 antibodies, in cerebrospinal fluid studies, 89-90
UJ181.4 antibodies, in cerebrospinal fluid studies, 90
Ulex europaeus agglutinin lectins, as tumor markers, in hemangioblastoma, 159
 in oligodendroglioma, 167
 in skin tumors, 187-188
 in vulvovaginal neoplasms, 108
Ultrastructural analysis, in leukemia of indeterminant lineage, 739
Urine testing, for lead, 447, 455
 in drug use/abuse, 301-309, 493-502
 alcohol, 358, 371-372
 gas chromatography/mass spectrometry in, 271-288
 population trends and, 289-299
 postmortem, sample collection for, 574
Uterine neoplasms, tumor markers in, 110-111

Vagina, neoplasms of, tumor markers in, 106-109
Vancomycin, nephrotoxicity of, 332
 ototoxicity of, 347
Vaquez-Osler disease (polycythemia vera), 863-869, 873-874, 876-878

Vascular changes, renal, drug-induced, 324-326
Vasoactive intestinal peptide, as tumor marker, 41
Vasodilators, digoxin interaction with, 489-490
Verapamil, digoxin interaction with, 489
Verruca vulgaris, tumor markers in, 180-181
Vimentin, as tumor marker, in astrocytoma, 166
 in cerebrospinal fluid studies, 91
 in choroid plexus tumors, 160
 in ependymoma, 168
 in immunohistochemistry, 63
 in melanocytic tumors, 186
 in meningioma, 156, 168
 in nerve sheath tumors, 154-156
 in ovarian neoplasms, 112
 in retinoblastoma, 171
 in skin tumors, 187-189
 in smooth muscle skin tumors, 188
 in vulvovaginal neoplasms, 109
Viomycin, ototoxicity of, 347
Viral oncogenes, in myelopoiesis, v-myb, 784
 in myeloproliferative disorders, v-erb, 778
 v-fms, 777
Vitamin D, in aluminum-induced osteomalacia, 413-414
Vitreous humor, collection of, for postmortem toxicology testing, 574, 582
Volatile substances, postmortem testing for, 581-584
 toxicity of, 399
 clinical evaluation in, 388-397
Vulva, neoplasms of, tumor markers in, 106-109

Water, aluminum in, 405
Wermer's syndrome, tumor markers in, 53-55
Western blot test, 218
White blood cell count, in agnogenic myeloid metaplasia, 832
 in chronic myelogenous leukemia, 827-828
Widmark formula, for alcohol consumption, 370-371

Xanthoastrocytoma, tumor markers in, 166-167

Yolk sac tumors, tumor markers in, 6

Zinc protoporphyrin, lead levels and, 448, 451-453
Zollinger-Ellison syndrome, tumor markers in, 54